In GBM cells, it was previously shown that AXT up to 150 μM does not affect cell viability but affects cell migration by downregulating matrix metalloproteinase (MMP)-2 in 50 μM AXT-treated A172 cell line [41]. This evidence concerns the gene MMP2 and glioblastoma.